Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Journal article

Wee EG. et al, (2019), Molecular therapy. Methods & clinical development, 14, 148 - 160

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA

Journal article

Moyo N. et al, (2019), Molecular Therapy - Methods & Clinical Development, 12, 32 - 46

APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon

Journal article

Armitage AE. et al, (2012), PLoS Genetics, 8, e1002550 - e1002550

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance

Journal article

Tenzer S. et al, (2009), Nature Immunology, 10, 636 - 646

P16-23. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance

Journal article

Tenzer S. et al, (2009), Retrovirology, 6, P252 - P252

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

Journal article

Nkolola JP. et al, (2004), Gene Therapy, 11, 1068 - 1080

Construction and immunogenicity in a prime–boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine

Journal article

Hanke T. et al, (2003), Journal of General Virology, 84, 361 - 368

Development of a DNA-MVA/HIVA vaccine for Kenya

Journal article

Hanke T. et al, (2002), Vaccine, 20, 1995 - 1998

Load More